My coronavirus vaccine pick Vaxart continues its recovery
Shares of Vaxart (VXRT) were up 21.77% today to $11.44 as of 3:15 p.m. New York time. You'll remember that Vaxart is my pick in my Volatility Portfolio for participating in the coronavirus vaccine race that plunged 47.6% from $16.97 on July 14 to to $8.90 a share on...
Incyte beats on earnings, revenue–but drops on lack of improved guidance
Shares of biotech Incyte (INCY) were down 2.60% as of 1:30 p.m. Tuesday on earnings and revenue that stomped Wall Street projections. The company reported second quarter adjusted earnings of $1.24 a share versus Wall Street projections for 50 cents a share. Earnings...
My fifth pick in my Special Report “10 Stocks to Beat Amazon” is a water stock, Danaher (DHR)
My fifth pick in my Special Report "10 Stocks to Beat Amazon" is a water stock, Danaher (DHR.) Danaher's trailing average annual returns don't look to be in Amazon's (AMZN) class--if all you do is look at the long-term 15-year period. Over a 15-year period Amazon's...
4th pick for Special Report 10 Stocks to Beat Amazon–SGEN
My fourth pick in my Special Report "10 Stocks to Beat Amazon" is a biotech, Seattle Genetics (SGEN). Biotech companies spend years developing their first successful drug. And then spend more years turning that first drug into a pipeline of drugs and expanded labels....
Raising my target price on Incyte to $120 a share after 58.5% gain in last 3 months
I admit it. I feel silly talking about price targets and valuations in this market. After all everything is just going to the sky. Infinity and Beyond!!! But, as silly as I may feel, I don't think the gods of investing have repealed the laws of valuation. At some...
Trump administration picks five coronavirus vaccine efforts to receive big government funding
The Trump administration has identified five companies that will get major government funding for the development of a coronavirus vaccine under Operation Warp Speed, the New York Times reported yesterday. The White House is expected to officially announce the names...
Selling Intrexon (now Precigen) after 293% gain today
To subscribe to JAM you need to fill in some details below including, ahem, some info on how you'll pay us. A subscription is $199 (although if you're subscribing with one of our special offers it will be lower) for a year for ongoing and continuing access to the...
AbbVie continues its run–picks up momentum from Allergan results
Shares of AbbVie (ABBV) tacked on another 1.32% today to a close at $96 continuing a run that began back on January 31 at $81.02. The trend picked up momentum on February 7 after the company reported fourth quarter earnings with better than expected sales for its...
Buying AbbVie today for my Dividend Portfolio with its 5.62% yield
To subscribe to JAM you need to fill in some details below including, ahem, some info on how you'll pay us. A subscription is $199 (although if you're subscribing with one of our special offers it will be lower) for a year for ongoing and continuing access to the...
FDA and Nektar both shock on company’s opioid drug candidate; I’d buy more on weakness
Yesterday an advisory joint committee at the U.S. Food & Drug Administration voted to reject Nektar's application for its new non-addictive opioid NKTR-181. The thinking--my thinking--was that the committee had structured the vote so that the most likely outcome...
Merck continues to ride cancer drug Keytruda higher
 Shares of Merck (MRK) closed up 3.50% today, October 29, after the company reported better than expected third quarter earnings. On a Non-GAAP basis earnings of $1.51 a share beat the Wall Street consensus by 27 cents a share. Revenue of $12.4 billion fell 6.7% year...Jim’s Stock Alerts
Download Jim’s eBook for Free
